Literature DB >> 15672611

Monoclonal antibodies against human tumor metastasis suppressor gene-1 (TMSG-1): preparation, characterization, and application.

Pei Fei1, Ning Junyu, You Jiangfeng, Yang Jingpin, Wang Yuping, Han Zhihui, Wang Jieliang, Cui Xianglin, Yang Shaomin, Zheng Jie.   

Abstract

To better understand the molecular mechanism of metastasis, the monoclonal antibody against tumor metastasis suppressor gene-1 (TMSG-1, one novel gene) was prepared, characterized, and applied in estimating the metastatic potential of human tumors. A dominant epitope, TMSG-1(15)--derived from TMSG-1--was automatically synthesized based on the Fmoc method, and the hapten was conjugated to Imject Maleimide activated mcKLH as a carrier protein. The antigen solution was used to immunize BALB/C mice. Hybridomas were generated and screened by ELISA for specific monoclonal antibodies, and their characterization was performed by Western blotting and immunohistochemical staining. The hybridoma cell line secreting anti-TMSG-1 antibody, designated C8, was established after primary ELISA screening and consequent rapid limited dilution. C8 was IgM in isotyping. The competitive inhibition assay showed that the antibody was TMSG-1 specific. Furthermore, in Western blotting, a protein band of about 45 kD was detected with nonmetastatic variant PC-3M-2B4 and PG-LH7 cells, but not with the isogenetic metastatic variant PC-3M-1E8 and PG-BE1 cells. Immunohistochemistry method showed that positive staining presented in the cytomembrane and cytoplasm of 2B4 and LH7 cells, while 1E8 and BE1 cells were non-reactive. The sections from paraffin-embedded blocks of human cancer (52 cases of breast carcinoma and 41 cases of colon cancer) were stained, showing strongly positive in non-metastatic tumor and weakly positive or negative in metastatic tumor; the strongly positive rate of TMSG-1 expression in human cancers were, respectively, 36%, 7.4%, 52.4%, and 35% in non-metastatic and metastatic breast cancer and non-metastatic and metastatic colon cancer (p = 0.02). The monoclonal antibody developed against synthetic peptide was TMSG-1 specific, and it has promise in Western blot and immunohistochemistry for detecting the TMSG-1 expression of cancer cells and tissues. It may provide an important tool in the study of TMSG-1 expression and function in both experimental and clinical studies. Furthermore, our tests confirmed that TMSG-1 protein has excellent inverse correlation to tumor metastasis potential, with the molecular weight of 45 kD (supporting the encoded protein containing 380 amino acids) and localization in cytomembrane and cytoplasm of tumor cell.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15672611     DOI: 10.1089/hyb.2004.23.318

Source DB:  PubMed          Journal:  Hybrid Hybridomics        ISSN: 1536-8599


  4 in total

1.  Identification of a novel short peptide seal specific to CD59 and its effect on HeLa cell growth and apoptosis.

Authors:  Bing Li; Mei-Hua Gao; Xian-Ming Chu; Ying-Jie Xu; Fan Yang
Journal:  Cell Oncol (Dordr)       Date:  2012-09-04       Impact factor: 6.730

2.  TMTP1, a novel tumor-homing peptide, specifically targets hematological malignancies and their metastases.

Authors:  Min Xiao; Zhenya Hong; Lishi Sun; Ying Wu; Na Zhang; Yanan Liu; Danfeng Luo; Jianfeng Zhou; Chunrui Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-10-25

3.  LASS2/TMSG1 inhibits growth and invasion of breast cancer cell in vitro through regulation of vacuolar ATPase activity.

Authors:  Fang Mei; Jiangfeng You; Beiying Liu; Mengxue Zhang; Jiangying Liu; Bo Zhang; Fei Pei
Journal:  Tumour Biol       Date:  2014-12-12

4.  LASS2 impairs proliferation of glioma stem cells and migration and invasion of glioma cells mainly via inhibition of EMT and apoptosis promotion.

Authors:  Wei-Jiang Zhao; Yi-Pu Fan; Guan-Yong Ou; Xin-Yu Qiao
Journal:  J Cancer       Date:  2022-04-18       Impact factor: 4.478

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.